🇺🇸 Clarithromycin Extended Release in United States

54 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Kidney Injury — 11 reports (20.37%)
  2. Drug Interaction — 11 reports (20.37%)
  3. Labelled Drug-Drug Interaction Medication Error — 5 reports (9.26%)
  4. Toxic Epidermal Necrolysis — 5 reports (9.26%)
  5. Dizziness — 4 reports (7.41%)
  6. Hyperkalaemia — 4 reports (7.41%)
  7. Nausea — 4 reports (7.41%)
  8. Rhabdomyolysis — 4 reports (7.41%)
  9. Anxiety — 3 reports (5.56%)
  10. Drug-Induced Liver Injury — 3 reports (5.56%)

Source database →

Clarithromycin Extended Release in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Clarithromycin Extended Release approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Clarithromycin Extended Release in United States?

University Medical Center Groningen is the originator. The local marketing authorisation holder may differ — check the official source linked above.